Industry Insider - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Insider

Getting the Balance Right

July 4, 2014

Pharmaceutical Technology

As the pharmaceutical industry comes to grips with the patent cliff, focus has shifted to the opportunities arising from emerging technologies. This article reviews the challenges that these developing medicines and medical applications encounter in achieving patent protection, contrasting the position in Europe with that in the United States and the impact it has on the future of pharmaceutical and biotechnology pipelines.

UK Biotech Gains Momentum

March 12, 2014

Pharmaceutical Technology

To gain insights into the current trends of the biotechnology sector in the United Kingdom, Pharmaceutical Technology Europe spoke with Steve Bates, chief executive officer of the BioIndustry Association (BIA), the trade association for biotech companies in the UK.

Turkey Increases R&D Incentives

February 2, 2014

Pharmaceutical Technology

Last year, the Turkish Government unveiled plans to position the country in the top 10 most-preferred locations for R&D investment in the pharmaceutical sector by 2023. This article provides an overview of the incentives introduced under the Technopolis Law and the R&D Act.

Unraveling the Mystery of Ireland's Pharm-Attractions

October 2, 2013

Pharmaceutical Technology

Ireland?s life-sciences sector has grown significantly since the 1960s. To gain insights into the competitive edge that Ireland offers to the pharmaceutical industry, Pharmaceutical Technology Europe spoke with Barry Heavey from IDA Ireland, which is a government agency responsible for attracting pharmaceutical and biotech companies to Ireland.

The Importance of Continued Investment in R&D

September 2, 2013

Pharmaceutical Technology

There has been a notable shift in interest for life-science companies over recent months from institutional investors investing through the public markets, but any plans to release further capital will rely on first-rate R&D.

The Dilemma with Orphan Drugs

August 1, 2013

Pharmaceutical Technology Europe

Orphan drugs for rare diseases are a major area of investment for pharmaceutical companies, but are they becoming too expensive for Europe to afford them?

Responding to the Patent Cliff

July 1, 2013

Pharmaceutical Technology Europe

As the dreaded patent cliff continues to haunt the pharmaceutical industry, some companies are resorting to desperate measures to delay generic drug entry into the market.

Pharma Job Cuts Cause Anxiety for European Governments

June 2, 2013

With downsizing occurring more frequently than ever within the pharmaceutical industry, is Europe doing enough to curb further job losses that could threaten the recovery of its economy?

Campaign Against Counterfeit Drugs Continues

May 2, 2013

Drug companies team up with INTERPOL to keep counterfeit medicines off the Internet and out of the hands of patients.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here